Search

Author/Creator Le, Dung T

1. Anti-PD-1 elicits regression of undifferentiated pleomorphic sarcomas with UV-mutation signatures. Issue 6 (8th June 2021)

Authors:
Cheung, Laurene S; Chen, Lingling; Oke, Teniola F; Schaffer, Thomas B; Boudadi, Karim; Ngo, Jillian T; Gross, John McMahon; Kemberling, Holly; Diaz, Luis A; Lipson, Evan; Sidhom, John-WIlliam; Taube, Janis; Anders, Robert; Pardoll, Drew M; Le, Dung T; Meyer, Christian F; Llosa, Nicolas
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 9:Issue 6(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Issue 5 (May 2021)

Authors:
Andre, Thierry; Amonkar, Mayur; Norquist, Josephine M; Shiu, Kai-Keen; Kim, Tae Won; Jensen, Benny Vittrup; Jensen, Lars Henrik; Punt, Cornelis J A; Smith, Denis; Garcia-Carbonero, Rocio; Sevilla, Isabel; De La Fouchardiere, Christelle; Rivera, Fernando; Elez, Elena; Diaz, Luis A; Yoshino, Takayu...
Journal:
Lancet oncology
Issue:
Volume 22:Issue 5(2021)
Page Start:
665
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Issue 7 (July 2016)

Authors:
Antonia, Scott J; López-Martin, José A; Bendell, Johanna; Ott, Patrick A; Taylor, Matthew; Eder, Joseph Paul; Jäger, Dirk; Pietanza, M Catherine; Le, Dung T; de Braud, Filippo; Morse, Michael A; Ascierto, Paolo A; Horn, Leora; Amin, Asim; Pillai, Rathi N; Evans, Jeffry; Chau, Ian; Bono, Petri; At...
Journal:
Lancet oncology
Issue:
Volume 17:Issue 7(2016:Jul.)
Page Start:
883
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Issue 11 (November 2016)

Authors:
Sharma, Padmanee; Callahan, Margaret K; Bono, Petri; Kim, Joseph; Spiliopoulou, Pavlina; Calvo, Emiliano; Pillai, Rathi N; Ott, Patrick A; de Braud, Filippo; Morse, Michael; Le, Dung T; Jaeger, Dirk; Chan, Emily; Harbison, Chris; Lin, Chen-Sheng; Tschaika, Marina; Azrilevich, Alex; Rosenberg, Jon...
Journal:
Lancet oncology
Issue:
Volume 17:Issue 11(2016:Nov.)
Page Start:
1590
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Issue 6 (June 2016)

Authors:
Muro, Kei; Chung, Hyun Cheol; Shankaran, Veena; Geva, Ravit; Catenacci, Daniel; Gupta, Shilpa; Eder, Joseph Paul; Golan, Talia; Le, Dung T; Burtness, Barbara; McRee, Autumn J; Lin, Chia-Chi; Pathiraja, Kumudu; Lunceford, Jared; Emancipator, Kenneth; Juco, Jonathan; Koshiji, Minori; Bang, Yung-Jue
Journal:
Lancet oncology
Issue:
Volume 17:Issue 6(2016:Jun.)
Page Start:
717
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Issue 5 (May 2022)

Authors:
Diaz, Luis A; Shiu, Kai-Keen; Kim, Tae-Won; Jensen, Benny Vittrup; Jensen, Lars Henrik; Punt, Cornelis; Smith, Denis; Garcia-Carbonero, Rocio; Benavides, Manuel; Gibbs, Peter; de la Fourchardiere, Christelle; Rivera, Fernando; Elez, Elena; Le, Dung T; Yoshino, Takayuki; Zhong, Wen Yan; Fogelman, ...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 5(2022)
Page Start:
659
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. (4th November 2015)

Authors:
Taylor, Matthew; Antonia, Scott; Bendell, Johanna; Calvo, Emiliano; Jäger, Dirk; de Braud, Filippo; Ott, Patrick A; Pietanza, M Catherine; Horn, Leora; Le, Dung T; Morse, Michael A; López-Martin, José A; Ascierto, Paolo A; Christensen, Olaf; Simon, Jason S; Lin, Chen-Sheng; Eder, Joseph Paul
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3(2015)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR). (4th November 2015)

Authors:
Le, Dung T; Crocenzi, Todd S; Urum, Jennifer N; Lutz, Eric R; Laheru, Daniel A; Sugar, Elizabeth A; Vonderheide, Robert H; Fisher, George A; Ko, Andrew H; Murphy, Aimee L; McDougall, Katherine; Ferber, Sandy; Brockstedt, Dirk G; Jaffee, Elizabeth M
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3(2015)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗